Evidence map›Paper›PMID 26040981›Full record

ArticleMolecular oncology2015

Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.

Pilar Bayo, Adriana Jou, Albrecht Stenzinger, Chunxuan Shao, Madeleine Gross, Alexandra Jensen, Niels Grabe, Christel Herold Mende, Pantelis Varvaki Rados, Juergen Debus and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Vocal folds irregular mucosal changes: a multimodal evaluation for diagnosis and genetic risk stratification.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Pluripotency Stemness and Cancer: More Questions than Answers.Advances in experimental medicine and biology · 2022
    Article
  13. Article
  14. Review
  15. HPVTranslational oncology · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Functional characterization of SOX2 as an anticancer target.Signal transduction and targeted therapy · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Pilar BayoDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany; Research Group Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany. Electronic address: pilarbz@gmail.com.
Adriana JouDepartment of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany; Oral Pathology, Universidade Federal do Rio Grande do Sul, Porto Alegre, CEP: 90035-003, Brazil. Electronic address: a.jou@Dkfz-Heidelberg.de.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, D-69120, Germany. Electronic address: albrecht.stenzinger@med.uni-heidelberg.de.
Chunxuan ShaoDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany. Electronic address: c.shao@Dkfz-Heidelberg.de.
Madeleine GrossDepartment of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany. Electronic address: MadeleineGross@gmx.de.
Alexandra JensenDepartment of Radiation Oncology, University Hospital Heidelberg, D-69120, Germany. Electronic address: alexandra.jensen@med.uni-heidelberg.de.
Niels GrabeHamamatsu Tissue Imaging and Analysis Center (TIGA), BIOQUANT, Heidelberg, D-69120, Germany; Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany. Electronic address: niels.grabe@bioquant.uni-heidelberg.de.
Christel Herold MendeExperimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Molecular Cell Biology Group, Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg, Germany. Electronic address: h.mende@med.uni-heidelberg.de.
Pantelis Varvaki RadosOral Pathology, Universidade Federal do Rio Grande do Sul, Porto Alegre, CEP: 90035-003, Brazil. Electronic address: pantelis@ufrgs.br.
Juergen DebusDepartment of Radiation Oncology, University Hospital Heidelberg, D-69120, Germany. Electronic address: juergen.debus@med.uni-heidelberg.de.
Wilko WeichertInstitute of Pathology, University Hospital Heidelberg, Heidelberg, D-69120, Germany. Electronic address: wilko.weichert@med.uni-heidelberg.de.
Peter K PlinkertDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany. Electronic address: peter_plinkert@med.uni-heidelberg.de.
Peter LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany. Electronic address: Peter.Lichter@Dkfz-Heidelberg.de.
Kolja FreierDepartment of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany. Electronic address: kolja.freier@med.uni-heidelberg.de.
Jochen HessDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, D-69120, Germany; Research Group Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center (DKFZ), Heidelberg, D-69120, Germany. Electronic address: j.hess@dkfz-heidelberg.de.
Heidelberg University · DEGerman Cancer Research Center · DEUniversidade Federal do Rio Grande do Sul · BRNational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrent gain on chromosome 3q26 encompassing the gene locus for the transcription factor SOX2 is a frequent event in human squamous cell carcinoma, including head and neck squamous cell carcinoma (HNSCC). Numerous studies demonstrated that SOX2 expression and function is related to distinct aspects of tumor cell pathophysiology. However, the underlying molecular mechanisms are not well understood, and the correlation between SOX2 expression and clinical outcome revealed conflicting data. Transcriptional profiling after silencing of SOX2 expression in a HNSCC cell line identified a set of up-regulated genes related to cell motility (e.g. VIM, FN1, CDH2). The inverse regulation of SOX2 and aforementioned genes was validated in 18 independent HNSCC cell lines from different anatomical sites. The inhibition of cell migration and invasion by SOX2 was confirmed by constant or conditional gene silencing and accelerated motility of HNSCC cells after SOX2 silencing was partially reverted by down-regulation of vimentin. In a retrospective study, SOX2 expression was determined by immunohistochemical staining on tissue microarrays containing primary tumor specimens of two independent HNSCC patient cohorts. Low SOX2 expression was found in 19.3% and 44.9% of primary tumor specimens, respectively. Univariate analysis demonstrated a statistically significant correlation between low SOX2 protein levels and reduced progression-free survival (Cohort I 51 vs. 16 months; Cohort II 33 vs. 12 months) and overall survival (Cohort I 150 vs. 37 months; Cohort II 33 vs. 16 months). Multivariate Cox proportional hazard model analysis confirmed that low SOX2 expression serves as an independent prognostic marker for HNSCC patients. We conclude that SOX2 inhibits tumor cell motility in HNSCC cells and that low SOX2 expression serves as a prognosticator to identify HNSCC patients at high risk for treatment failure.

Indexed as

Gene DeletionAdultAgedAged, 80 and overCarcinoma, Squamous CellCell Line, TumorCell MovementDown-RegulationFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSOX2 protein, humanSOXB1 Transcription FactorsVimentinCell motilityGene expression profilingImmunohistochemistryPrognostic biomarkerTissue microarray

Identifiers

PMID26040981
PMCPMC5528792
OpenAlexW1638321123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.